Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Net Margin (2020 - 2025)

Cytek Biosciences' Net Margin history spans 6 years, with the latest figure at 70.93% for Q4 2025.

  • For Q4 2025, Net Margin fell 8771.0% year-over-year to 70.93%; the TTM value through Dec 2025 reached 33.02%, down 3002.0%, while the annual FY2025 figure was 33.02%, 3002.0% down from the prior year.
  • Net Margin reached 70.93% in Q4 2025 per CTKB's latest filing, down from 10.48% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 16.78% in Q4 2024 to a low of 70.93% in Q4 2025.
  • Average Net Margin over 5 years is 9.13%, with a median of 7.3% recorded in 2022.
  • Peak YoY movement for Net Margin: surged 1528bps in 2024, then tumbled -8771bps in 2025.
  • A 5-year view of Net Margin shows it stood at 1.01% in 2021, then surged by 625bps to 7.3% in 2022, then rose by 29bps to 9.45% in 2023, then skyrocketed by 78bps to 16.78% in 2024, then tumbled by -523bps to 70.93% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Net Margin are 70.93% (Q4 2025), 10.48% (Q3 2025), and 12.24% (Q2 2025).